Vivos Therapeutics (VVOS) Equity Average (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Equity Average data on file, last reported at -$1.3 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$1.3 million, down 121.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 121.75% YoY), and the FY2025 annual result was $3.2 million, down 23.44% from the prior year.
• Equity Average eased to -$1.3 million in Q1 2026 per VVOS's latest filing, from $491000.0 in the prior quarter.
• Over five years, Equity Average peaked at $23.3 million in Q1 2022 and troughed at -$1.3 million in Q1 2026.
• A 5-year average of $6.2 million and a median of $4.5 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2026: Equity Average jumped 3317.72% in 2024, then slumped 121.75% in 2026.
• A 5-year view of Equity Average shows it stood at $7.3 million in 2022, then sank by 96.88% to $228500.0 in 2023, then jumped by 3317.72% to $7.8 million in 2024, then tumbled by 93.71% to $491000.0 in 2025, then tumbled by 373.73% to -$1.3 million in 2026.
• Business Quant data shows VVOS's Equity Average at -$1.3 million in Q1 2026, $491000.0 in Q4 2025, and $3.6 million in Q3 2025.